Founded in 2016 and based in Berlin, Germany, Cellbricks is a pioneering biotechnology company at the forefront of 3D-bioprinted tissue therapeutics. Established by CEO Alexander Leutner and Chief Scientific Officer Joachim von Arnim, the company initially concentrated on developing advanced 3D bioprinters. In 2021, Cellbricks strategically shifted its focus to become a leading provider of bioprinted tissue therapeutics, marking a significant leap forward in regenerative medicine.

In 2024, Cellbricks garnered widespread acclaim by winning a World Future Awards for Best 3D-Bioprinted Therapeutics Innovation. This renowned award highlights their avant-garde work in creating functional, implantable tissue that has the potential to restore organ function and significantly enhance patient health. The company’s innovative technology addresses a critical challenge in modern medicine: the shortage of donor organs. By producing bioprinted tissue on demand, Cellbricks provides a viable and efficient alternative to traditional organ transplants, reducing patient wait times and offering a more sustainable solution.

Cellbricks’ vision includes establishing Biofabrication Centers (CBCs) in key metropolitan areas globally. These centers will collaborate with hospitals to deliver organ tissue on demand, transforming medical treatment delivery and meeting the growing global need for life-saving tissue. With ongoing innovation and multiple patents filed, Cellbricks remains dedicated to improving patient outcomes and reducing healthcare costs. Their advancements not only promise a longer, healthier life for patients but also a significant reduction in the economic burden on healthcare systems worldwide.